Torrent pharma Q3 result: Torrent Pharma released financial results for the third quarter of FY 2025 on 24 January. The company’s net profit increased by 13.54 percent to Rs 503 crore in the quarter ended December 31. Whereas in the same period of a year ago, the company’s profit was Rs 443 crore. Stock filing revealed that the pharmaceutical firm had a net profit of Rs 453 crore in the September quarter. The company’s shares fell 0.45 percent to close at Rs 3,248.9 on NSE. Apart from this, the company has announced an interim dividend of Rs 26 per equity share of Rs 5 per equity share.
Minor increase in net sales
The company’s filing shows that the company’s net sales increased slightly to Rs 2,762 crore in the reported quarter. Which was Rs 2,691 crore in the same period of the last financial year. The company said that net sales were recorded at Rs 2,831 crore in the September quarter.
The firm said that the speed of its strong business in India was lost due to the shutdown of CMO and 17 percent decline in BRLs from year to year. The company’s statement further stated that “no insulin CMO was sold in the quarter but the dispatch has been resumed from January 2025.”
Domestic investors bought shares worth Rs 2,402 crore, foreign investors sold equity of Rs 2,758
India Revenue increased
The company said that its revenue of India was Rs 1,581 crore. In which focus therapy recorded a 12 percent increase due to better performance.
“Based on MAT, Torrent launched new products and performed Majubat. With its help, the company has performed better than the market in focused therapies. The IPM has 20 brands of Torrent in Chop 500 brands. In which 13 brands are more than 100 crores. ”
Additionally, its US business revenue was reduced by 1% to Rs 271 crore. In the context of Constand Currency, the Revenue stood at $ 32 million. Which is 3% less than the same period of previous year.
Disclaimer: (Information provided here is being given only for information. It is necessary to mention here that the investment in the market is subject to risks. Always consult expert before investing as an investor. It is never advised to apply here.)